CSTONE PHARMA-B (02616) obtained the director Yang Jianxin and senior management to increase their holdings by 2.42 million shares.

CSTONE PHARMA-B (02616) announced that the CEO, R&D President and Executive Director, Dr. Yang Jianxin, along with other directors and senior management, have collectively purchased 2.4205 million shares of the company's stock on the open market in June 2026. Dr. Yang purchased 1.2375 million shares. Since becoming CEO in August 2022, Dr. Yang has accumulated a total of 13.7145 million shares through open market purchases. Following this share increase, as of the date of this announcement, Dr. Yang holds shares equivalent to approximately 5.26% of the company's total issued shares. Dr. Yang, other directors, and senior management have expressed confidence in the company's research and development achievements, commercial progress, and long-term business development. Specifically, the company's core pipeline CS2009 (PD-1/VEGF/CTLA-4 triple-specific antibody) global multicenter Phase II clinical trial is progressing smoothly. The latest clinical data is scheduled to be announced in the mid-year performance report and at the 2026 European Society for Medical Oncology (ESMO) annual meeting. Plans are also in place to communicate the Phase III global multicenter registration study (MRCT) with the US Food and Drug Administration (FDA) by the end of this year, and to initiate the first batch of global Phase III MRCT. In June 2026, the company also repurchased 4.597 million shares of stock (this share repurchase), with all repurchased shares planned to be cancelled. This share repurchase demonstrates the company's strong confidence in its long-term business development and reflects its commitment to enhancing shareholder value and continuously improving its capital return mechanism.